Biotech Values

[DewDiligence]

ABBV/ENTA—Ritonavir boosting is a clear indication that there's room for improvement [in ABBV’s HCV regimen].

I agree in part. ABBV’s ABT-450-based regimen uses ritonavir at half the normal PK-boosting dose; if this regimen were using ritonavir at full strength, it would be much more of a detriment to commercial uptake.